These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9708899)
1. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. Cabot MC; Han TY; Giuliano AE FEBS Lett; 1998 Jul; 431(2):185-8. PubMed ID: 9708899 [TBL] [Abstract][Full Text] [Related]
2. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Goulding CW; Giuliano AE; Cabot MC Cancer Lett; 2000 Feb; 149(1-2):143-51. PubMed ID: 10737718 [TBL] [Abstract][Full Text] [Related]
3. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cabot MC; Giuliano AE; Han TY; Liu YY Cancer Res; 1999 Feb; 59(4):880-5. PubMed ID: 10029079 [TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC Cancer; 1999 Jul; 86(2):300-11. PubMed ID: 10421266 [TBL] [Abstract][Full Text] [Related]
5. Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Wang H; Giuliano AE; Cabot MC Mol Cancer Ther; 2002 Jul; 1(9):719-26. PubMed ID: 12479368 [TBL] [Abstract][Full Text] [Related]
6. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Jiang XR; Kelsey SM; Wu YL; Newland AC Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760 [TBL] [Abstract][Full Text] [Related]
7. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277 [TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Pallis M; Russell N Blood; 2000 May; 95(9):2897-904. PubMed ID: 10779437 [TBL] [Abstract][Full Text] [Related]
10. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Friche E; Jensen PB; Nissen NI Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375 [TBL] [Abstract][Full Text] [Related]
11. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. te Boekhorst PA; van Kapel J; Schoester M; Sonneveld P Cancer Chemother Pharmacol; 1992; 30(3):238-42. PubMed ID: 1352739 [TBL] [Abstract][Full Text] [Related]
12. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15. Uchiyama-Kokubu N; Watanabe T; Cohen D Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863 [TBL] [Abstract][Full Text] [Related]
13. Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: influence of drug transport abnormalities. Côme MG; Bettaieb A; Skladanowski A; Larsen AK; Laurent G Int J Cancer; 1999 May; 81(4):580-7. PubMed ID: 10225448 [TBL] [Abstract][Full Text] [Related]
14. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia. Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923 [TBL] [Abstract][Full Text] [Related]
15. Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of P-glycoprotein. Azare J; Pankova-Kholmyansky I; Salnikow K; Cohen D; Flescher E Oncol Res; 2001; 12(8):315-23. PubMed ID: 11589302 [TBL] [Abstract][Full Text] [Related]
16. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers. Pilarski LM; Yatscoff RW; Murphy GF; Belch AR Leukemia; 1998 Apr; 12(4):505-9. PubMed ID: 9557608 [TBL] [Abstract][Full Text] [Related]
17. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment. Jetté L; Murphy GF; Béliveau R Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733 [TBL] [Abstract][Full Text] [Related]
18. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance. Uchiyama-Kokubu N; Watanabe T; Nakajima M Anticancer Drugs; 2000 Aug; 11(7):583-90. PubMed ID: 11036963 [TBL] [Abstract][Full Text] [Related]